Pancreatic Cancer Drug Receives FDA Orphan Drug Designation

06:30 EDT 21 Jun 2017 | PharmPro

Intezyne Technologies granted Orphan Drug designation for IT-139 in pancreatic cancer. A previously completed trial showed that the drug was well-tolerated, with manageable side effects, and successfully demonstrated anti-tumor activity.
Contributed Author: 
Intezyne Technologies, Inc.

Original Article: Pancreatic Cancer Drug Receives FDA Orphan Drug Designation


More From BioPortfolio on "Pancreatic Cancer Drug Receives FDA Orphan Drug Designation"

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pancreatic Cancer
The pancreas secretes a number of important hormones into the digestive tract and the blood stream. Cancers are most commonly exocrine than endocrine (neuroendocrine) tumors. Functional tumors secrete hormones; Insulinoma, Gastrinoma, Somatostatinoma, VI...